Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Carbon chain length modulates MDA-MB-231 breast cancer cell killing mechanisms by mitochondrially targeted aryl-urea fatty acids.

Murray M, Roseblade A, Chen Y, Bourget K, Rawling T.

ChemMedChem. 2019 Nov 26. doi: 10.1002/cmdc.201900577. [Epub ahead of print]

PMID:
31773850
2.

Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.

Murray M, Gillani TB, Rawling T, Nair PC.

AAPS J. 2019 Oct 21;21(6):107. doi: 10.1208/s12248-019-0374-2.

PMID:
31637538
3.

Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics.

Mostyn SN, Wilson KA, Schumann-Gillett A, Frangos ZJ, Shimmon S, Rawling T, Ryan RM, O'Mara ML, Vandenberg RJ.

Elife. 2019 Oct 17;8. pii: e47150. doi: 10.7554/eLife.47150.

4.

l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.

Billings JL, Gordon SL, Rawling T, Doble PA, Bush AI, Adlard PA, Finkelstein DI, Hare DJ.

J Neurochem. 2019 Jul;150(1):88-106. doi: 10.1111/jnc.14676. Epub 2019 Mar 28.

PMID:
30716176
5.

Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.

Mostyn SN, Rawling T, Mohammadi S, Shimmon S, Frangos ZJ, Sarker S, Yousuf A, Vetter I, Ryan RM, Christie MJ, Vandenberg RJ.

J Med Chem. 2019 Mar 14;62(5):2466-2484. doi: 10.1021/acs.jmedchem.8b01775. Epub 2019 Feb 20.

6.

Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.

Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M.

AAPS J. 2019 Jan 9;21(2):15. doi: 10.1208/s12248-018-0262-1.

PMID:
30627802
7.

Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells.

Al-Zubaidi Y, Pazderka C, Koolaji N, Rahman MK, Choucair H, Umashankar B, Bourget K, Chen Y, Rawling T, Murray M.

Eur J Pharm Sci. 2019 Mar 1;129:87-98. doi: 10.1016/j.ejps.2018.12.015. Epub 2018 Dec 29.

PMID:
30597206
8.

Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives.

Garrastazu Pereira G, Rawling T, Pozzoli M, Pazderka C, Chen Y, Dunstan CR, Murray M, Sonvico F.

Nanomaterials (Basel). 2018 Oct 13;8(10). pii: E825. doi: 10.3390/nano8100825.

9.

Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and Their Application in Drug Discovery.

Pazderka CW, Oliver B, Murray M, Rawling T.

Curr Med Chem. 2018 Sep 26. doi: 10.2174/0929867325666180927100120. [Epub ahead of print]

PMID:
30259807
10.

Antiproliferative activities of alkaloid-like compounds.

Xu X, Rawling T, Roseblade A, Bishop R, Ung AT.

Medchemcomm. 2017 Oct 25;8(11):2105-2114. doi: 10.1039/c7md00435d. eCollection 2017 Nov 1.

11.

Carboxylate Analogues of Aryl-Urea-Substituted Fatty Acids That Target the Mitochondria in MDA-MB-231 Breast Cancer Cells to Promote Cell Death.

Koolaji N, Rawling T, Bourget K, Murray M.

ChemMedChem. 2018 May 23;13(10):1036-1043. doi: 10.1002/cmdc.201800018. Epub 2018 Apr 23.

PMID:
29603659
12.

Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord.

Winters BL, Rawling T, Vandenberg RJ, Christie MJ, Bhola RF, Imlach WL.

Br J Pharmacol. 2018 Jun;175(12):2337-2347. doi: 10.1111/bph.14189. Epub 2018 Apr 14.

13.

Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.

Murray M, Gillani TB, Ghassabian S, Edwards RJ, Rawling T.

Eur J Pharm Sci. 2018 Mar 1;114:55-63. doi: 10.1016/j.ejps.2017.12.003. Epub 2017 Dec 7.

PMID:
29223619
14.

A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells.

Rawling T, Choucair H, Koolaji N, Bourget K, Allison SE, Chen YJ, Dunstan CR, Murray M.

J Med Chem. 2017 Oct 26;60(20):8661-8666. doi: 10.1021/acs.jmedchem.7b00701. Epub 2017 Oct 5.

PMID:
28921987
15.

A novel synthetic analogue of ω-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells.

Dyari HRE, Rawling T, Chen Y, Sudarmana W, Bourget K, Dwyer JM, Allison SE, Murray M.

FASEB J. 2017 Dec;31(12):5246-5257. doi: 10.1096/fj.201700033R. Epub 2017 Aug 10.

PMID:
28798154
16.

Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2.

Mostyn SN, Carland JE, Shimmon S, Ryan RM, Rawling T, Vandenberg RJ.

ACS Chem Neurosci. 2017 Sep 20;8(9):1949-1959. doi: 10.1021/acschemneuro.7b00105. Epub 2017 Jun 15.

PMID:
28574249
17.

Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs.

Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T.

Pharmacol Ther. 2015 Jun;150:109-28. doi: 10.1016/j.pharmthera.2015.01.008. Epub 2015 Jan 17. Review.

PMID:
25603423
18.

Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.

Gillani TB, Rawling T, Murray M.

Chem Res Toxicol. 2015 Jan 20;28(1):92-102. doi: 10.1021/tx500373g. Epub 2014 Dec 23.

PMID:
25489883
19.

COL6A3 is regulated by leptin in human adipose tissue and reduced in obesity.

McCulloch LJ, Rawling TJ, Sjöholm K, Franck N, Dankel SN, Price EJ, Knight B, Liversedge NH, Mellgren G, Nystrom F, Carlsson LM, Kos K.

Endocrinology. 2015 Jan;156(1):134-46. doi: 10.1210/en.2014-1042.

PMID:
25337653
20.

Selective inhibition of human solute carrier transporters by multikinase inhibitors.

Johnston RA, Rawling T, Chan T, Zhou F, Murray M.

Drug Metab Dispos. 2014 Nov;42(11):1851-7. doi: 10.1124/dmd.114.059097. Epub 2014 Aug 27.

PMID:
25165131
21.

Synthetic ω-3 epoxyfatty acids as antiproliferative and pro-apoptotic agents in human breast cancer cells.

Dyari HR, Rawling T, Bourget K, Murray M.

J Med Chem. 2014 Sep 11;57(17):7459-64. doi: 10.1021/jm501083y. Epub 2014 Aug 29.

PMID:
25144895
22.

Lipid analogues as potential drugs for the regulation of mitochondrial cell death.

Murray M, Dyari HR, Allison SE, Rawling T.

Br J Pharmacol. 2014 Apr;171(8):2051-66. doi: 10.1111/bph.12417. Review.

23.

Cell-derived microparticles: new targets in the therapeutic management of disease.

Roseblade A, Luk F, Rawling T, Ung A, Grau GE, Bebawy M.

J Pharm Pharm Sci. 2013;16(2):238-53. Review.

24.

A role for SPARC in the moderation of human insulin secretion.

Harries LW, McCulloch LJ, Holley JE, Rawling TJ, Welters HJ, Kos K.

PLoS One. 2013 Jun 28;8(6):e68253. doi: 10.1371/journal.pone.0068253. Print 2013.

25.

Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.

Cui PH, Rawling T, Gillani TB, Bourget K, Wang XS, Zhou F, Murray M.

Biochem Pharmacol. 2013 Aug 1;86(3):419-27. doi: 10.1016/j.bcp.2013.05.014. Epub 2013 May 31.

PMID:
23732299
26.

Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2.

Cui PH, Rawling T, Bourget K, Kim T, Duke CC, Doddareddy MR, Hibbs DE, Zhou F, Tattam BN, Petrovic N, Murray M.

J Med Chem. 2012 Aug 23;55(16):7163-72. doi: 10.1021/jm300673z. Epub 2012 Aug 2.

PMID:
22822908
27.

Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.

Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, Edwards RJ, Cui PH, Murray M.

Biochem Pharmacol. 2012 Jul 15;84(2):215-23. doi: 10.1016/j.bcp.2012.04.001. Epub 2012 Apr 10.

PMID:
22513143
28.
29.

Facile and stereoselective synthesis of (Z)-15-octadecenoic acid and (Z)-16-nonadecenoic acid: monounsaturated omega-3 fatty acids.

Rawling T, Duke CC, Cui PH, Murray M.

Lipids. 2010 Feb;45(2):159-65. doi: 10.1007/s11745-009-3378-3.

PMID:
20069386
30.

Ruthenium phthalocyanine-bipyridyl dyads as sensitizers for dye-sensitized solar cells: dye coverage versus molecular efficiency.

Rawling T, Austin C, Buchholz F, Colbran SB, McDonagh AM.

Inorg Chem. 2009 Apr 6;48(7):3215-27. doi: 10.1021/ic802087n.

PMID:
19278209
31.

Optical and redox properties of ruthenium phthalocyanine complexes tuned with axial ligand substituents.

Rawling T, Xiao H, Lee ST, Colbran SB, McDonagh AM.

Inorg Chem. 2007 Apr 2;46(7):2805-13. Epub 2007 Mar 2.

PMID:
17330967
32.

Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.

Horvath N, Hahn U, Joshua D, Dyson P, Gibson J, Stevens J, Rawling T, Barrow L, Brown R, Stephens S, Gower G, Norman J, Mills B, To LB.

Intern Med J. 2004 Apr;34(4):167-75.

PMID:
15086696
33.

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.

Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP.

Cytotherapy. 2003;5(6):534-41.

PMID:
14660049
34.

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.

To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, Gibson J, Lewis I, Swart B, Marty J, Rawling T, Ashman L, Charles S, Cohen B.

Bone Marrow Transplant. 2003 Mar;31(5):371-8.

PMID:
12634728
35.

A phase I study of the GM-CSF antagonist E21R.

Olver IN, Hercus T, Lopez A, Vadas M, Somogyi AA, Doyle I, Foster DJ, Keefe D, Taylor A, Brown M, To LB, Cole J, Rawling T, Cambareri B, Myers M, Olszewski N, Bastiras S, Senn C, Hey A, Verma M, Wigley P.

Cancer Chemother Pharmacol. 2002 Sep;50(3):171-8. Epub 2002 Jul 3.

PMID:
12203098
36.

Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF.

Lie AK, Hui CH, Rawling T, Dyson PG, Thorp D, Benic J, Rawling CM, Toogood I, Horvath N, Simmons PJ, To LB.

Bone Marrow Transplant. 1998 Nov;22(9):853-7.

37.
38.

Standardization of the CFU-GM assay using hematopoietic growth factors.

Lewis ID, Rawling T, Dyson PG, Haylock DN, Juttner CA, To LB.

J Hematother. 1996 Dec;5(6):625-30.

PMID:
9117251
39.

Increased levels of megakaryocyte progenitors in peripheral blood mobilised by chemotherapy and/or haemopoietic growth factor protocols.

Dyson PG, Jackson KA, McClure BJ, Rawling TP, To LB.

Bone Marrow Transplant. 1996 Oct;18(4):705-12.

PMID:
8899184

Supplemental Content

Loading ...
Support Center